Update in treatment of uveitic macular edema

Spyridon Koronis,1 Panagiotis Stavrakas,2 Miltiadis Balidis,1 Nikolaos Kozeis,1 Paris G Tranos1 1Ophthalmica Eye Institute, Thessaloniki, Greece; 2Department of Ophthalmology, Attikon University Hospital, Athens, Greece Abstract: Macular edema (ME) represents the most common cause for visual loss...

Full description

Bibliographic Details
Main Authors: Koronis S, Stavrakas P, Balidis M, Kozeis N, Tranos PG
Format: Article
Language:English
Published: Dove Medical Press 2019-02-01
Series:Drug Design, Development and Therapy
Subjects:
Online Access:https://www.dovepress.com/update-in-treatment-of-uveitic-macular-edema-peer-reviewed-article-DDDT
id doaj-43bf3d876bab46f3ad0d202f6e51618a
record_format Article
spelling doaj-43bf3d876bab46f3ad0d202f6e51618a2020-11-24T21:13:44ZengDove Medical PressDrug Design, Development and Therapy1177-88812019-02-01Volume 1366768044146Update in treatment of uveitic macular edemaKoronis SStavrakas PBalidis MKozeis NTranos PGSpyridon Koronis,1 Panagiotis Stavrakas,2 Miltiadis Balidis,1 Nikolaos Kozeis,1 Paris G Tranos1 1Ophthalmica Eye Institute, Thessaloniki, Greece; 2Department of Ophthalmology, Attikon University Hospital, Athens, Greece Abstract: Macular edema (ME) represents the most common cause for visual loss among uveitis patients. The management of uveitic macular edema (UME) may be challenging, due to its often recalcitrant nature. Corticosteroids remain the mainstay of treatment, through their capability of effectively controlling inflammation and the associated ME. Topical steroids may be effective in milder cases of UME, particularly in edema associated with anterior uveitis. Posterior sub-Tenon and orbital floor steroids, as well as intravitreal steroids often induce rapid regression of UME, although this may be followed by recurrence of the pathology. Intravitreal corticosteroid implants provide sustained release of steroids facilitating regression of ME with less frequent injections. Topical nonsteroidal anti-inflammatory drugs may provide a safe alternative or adjuvant therapy to topical steroids in mild UME, predominantly in cases with underlying anterior uveitis. Immunomodulators including methotrexate, mycophenolate mofetil, tacrolimus, azathioprine, and cyclosporine, as well as biologic agents, notably the anti-tumor necrosis factor-α monoclonal antibodies adalimumab and infliximab, may accomplish the control of inflammation and associated ME in refractory cases, or enable the tapering of steroids. Newer biotherapies have demonstrated promising outcomes and may be considered in persisting cases of UME. Keywords: uveitis, macular edema, treatment, corticosteroids, dexamethasone implant, NSAIDs, anti-TNFα, interferonshttps://www.dovepress.com/update-in-treatment-of-uveitic-macular-edema-peer-reviewed-article-DDDTuveitisuveitic macular edematreatment.
collection DOAJ
language English
format Article
sources DOAJ
author Koronis S
Stavrakas P
Balidis M
Kozeis N
Tranos PG
spellingShingle Koronis S
Stavrakas P
Balidis M
Kozeis N
Tranos PG
Update in treatment of uveitic macular edema
Drug Design, Development and Therapy
uveitis
uveitic macular edema
treatment.
author_facet Koronis S
Stavrakas P
Balidis M
Kozeis N
Tranos PG
author_sort Koronis S
title Update in treatment of uveitic macular edema
title_short Update in treatment of uveitic macular edema
title_full Update in treatment of uveitic macular edema
title_fullStr Update in treatment of uveitic macular edema
title_full_unstemmed Update in treatment of uveitic macular edema
title_sort update in treatment of uveitic macular edema
publisher Dove Medical Press
series Drug Design, Development and Therapy
issn 1177-8881
publishDate 2019-02-01
description Spyridon Koronis,1 Panagiotis Stavrakas,2 Miltiadis Balidis,1 Nikolaos Kozeis,1 Paris G Tranos1 1Ophthalmica Eye Institute, Thessaloniki, Greece; 2Department of Ophthalmology, Attikon University Hospital, Athens, Greece Abstract: Macular edema (ME) represents the most common cause for visual loss among uveitis patients. The management of uveitic macular edema (UME) may be challenging, due to its often recalcitrant nature. Corticosteroids remain the mainstay of treatment, through their capability of effectively controlling inflammation and the associated ME. Topical steroids may be effective in milder cases of UME, particularly in edema associated with anterior uveitis. Posterior sub-Tenon and orbital floor steroids, as well as intravitreal steroids often induce rapid regression of UME, although this may be followed by recurrence of the pathology. Intravitreal corticosteroid implants provide sustained release of steroids facilitating regression of ME with less frequent injections. Topical nonsteroidal anti-inflammatory drugs may provide a safe alternative or adjuvant therapy to topical steroids in mild UME, predominantly in cases with underlying anterior uveitis. Immunomodulators including methotrexate, mycophenolate mofetil, tacrolimus, azathioprine, and cyclosporine, as well as biologic agents, notably the anti-tumor necrosis factor-α monoclonal antibodies adalimumab and infliximab, may accomplish the control of inflammation and associated ME in refractory cases, or enable the tapering of steroids. Newer biotherapies have demonstrated promising outcomes and may be considered in persisting cases of UME. Keywords: uveitis, macular edema, treatment, corticosteroids, dexamethasone implant, NSAIDs, anti-TNFα, interferons
topic uveitis
uveitic macular edema
treatment.
url https://www.dovepress.com/update-in-treatment-of-uveitic-macular-edema-peer-reviewed-article-DDDT
work_keys_str_mv AT koroniss updateintreatmentofuveiticmacularedema
AT stavrakasp updateintreatmentofuveiticmacularedema
AT balidism updateintreatmentofuveiticmacularedema
AT kozeisn updateintreatmentofuveiticmacularedema
AT tranospg updateintreatmentofuveiticmacularedema
_version_ 1716748395965579264